Results 91 to 100 of about 61,480 (319)

Evaluation of simvastatin and CYP3A4-inhibitor interactions in an inpatient population [PDF]

, 2023
Daniel Boamah, Liam Bastian, Michael Wilcock   +2 more
openalex   +1 more source

Efficacy and safety of perampanel as first adjunctive therapy in patients with focal‐onset seizures or generalized tonic‐clonic seizures in four post‐marketing studies across regions

Epilepsia Open, EarlyView.
Abstract Objective Early response to anti‐seizure medication (ASM) is associated with a favorable prognosis in patients with epilepsy. Research is required to confirm existing data on the clinical use of perampanel as first adjunctive therapy in different patient groups and different regions.
Stefano Meletti, Vineet Punia, Amitabh Dash, Anna Lisa Gentile, Ricardo Sáinz‐Fuertes, Samantha Goldman, Tobias Goldmann, Anna Patten, Dinesh Kumar, Leock Y. Ngo, Bernhard J. Steinhoff   +10 more
wiley   +1 more source

Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors

Drug Design, Development and Therapy, 2020
Yun-Ting Zhu,1,* Zan Teng,2,3,* Yi-Fan Zhang,1 Wei Li,1 Li-Xia Guo,1 Yun-Peng Liu,2,3 Xiu-Juan Qu,2,3 Quan-Ren Wang,4 Si-Yuan Mao,4 Xiao-Yan Chen,1 Da-Fang Zhong1 1State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese ...
Zhu YT, Teng Z, Zhang YF, Li W, Guo LX, Liu YP, Qu XJ, Wang QR, Mao SY, Chen XY, Zhong DF   +10 more
doaj  

Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism

Pharmaceutical Biology, 2018
Context: Ginkgo leaf tablets (GLTs) and losartan are often simultaneously used for the treatment of hypertension in Chinese clinics. However, the herb–drug interaction between GLT and losartan is still unknown.
Baiping Dong, Suowei Yuan, Jinsheng Hu, Yanzhen Yan   +3 more
doaj   +1 more source

A new metabolic path in type 3 rickets. [PDF]

FEBS J
Rickets, a bone disorder, was historically categorised into either nutritional (vitamin D deficiency) or genetic forms involving loss‐of‐function mutations in mineral metabolism. Recently, a new mechanism, type 3 rickets, was discovered to be caused by a gain‐of‐function mutation in CYP3A4 (Ile301Thr).
Senda T, Hirota Y.
europepmc   +2 more sources

Kidney Transplant Recipients Carrying the CYP3A4*22 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations

American Journal of Transplantation, 2015
CYP3A4*22 is an allelic variant of the cytochrome P450 3A4 associated with a decreased activity. Carriers of this polymorphism may require reduced tacrolimus (Tac) doses to reach the target residual concentrations (Co).
N. Pallet, A. Jannot, M. El Bahri, I. Étienne, M. Buchler, B. H. de Ligny, G. Choukroun, C. Colosio, A. Thierry, C. Vigneau, B. Moulin, Y. Le Meur, A. Heng, J. Subra, C. Legendre, P. Beaune, C. Alberti, M. Loriot, E. Thervet   +18 more
semanticscholar   +1 more source

Integrated Anatomical, Chemical, Biological and Computational Studies Approach of Myrcia sylvatica (G. Mey) DC. A Multifaceted Insight Into a Promising Amazonian Species

Flavour and Fragrance Journal, EarlyView.
This study presents an integrated anatomical, chemical, biological, and computational analysis of Myrcia sylvatica, revealing key bioactive compounds with antioxidant and toxicological potential, and identifying spathulenol and globulol as promising acetylcholinesterase inhibitors with favourable pharmacokinetic properties. ABSTRACT Myrcia sylvatica (G.
Eliza de Jesus Barros dos Santos, Zelina Ataíde Correia, Ely Simone Cajueiro Gurgel, Leonardo Souza da Costa, Mabrouk Horchani, Hayet Edziri, Ravendra Kumar, Anderson de Santana Botelho, Karyme do Socorro de Souza Vilhena, Eloisa Helena de Aguiar Andrade, Mozaniel Santana de Oliveira   +10 more
wiley   +1 more source

No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects

International Journal of Cancer, EarlyView.
What's New? Venous thromboembolism (VTE) is common in cancer patients, with direct oral anticoagulants, including rivaroxaban, recommended as first‐line therapy. However, oral anticoagulant use is limited due to the growing use of targeted therapy and concerns about drug‐drug interactions.
Esther M. Hollander, Alessandra I. G. Buma, Jenneke Leentjens, Paddy K. C. Janssen, Michel M. van den Heuvel, David M. Burger, Berber Piet, Rob ter Heine   +7 more
wiley   +1 more source

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration‐Resistant Prostate Cancer

The Journal of Clinical Pharmacology, EarlyView.
Abstract The poly(ADP‐ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene‐mutated metastatic castration‐resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe.
Mark Hadigol, Jason H. Williams, Haihong Shi, Derek Z. Yang, Justin Hoffman, Diane D. Wang   +5 more
wiley   +1 more source

Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study [PDF]

, 2023
Maxim Grymonprez, Laura Carnoy, Andreas Capiau, Koen Boussery, Els Mehuys, Tine L. De Backer, Stéphane Steurbaut, Lies Lahousse   +7 more
openalex   +1 more source